Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Survival and prognostic factors in childhood medulloblastoma: A Brazilian single center experience from 1995 to 2016.

Bleil CB, Bizzi JWJ, Bedin A, de Oliveira FH, Antunes ÁCM.

Surg Neurol Int. 2019 Jun 25;10:120. doi: 10.25259/SNI-237-2019. eCollection 2019.

2.

Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis.

Thompson EM, Hielscher T, Bouffet E, Remke M, Luu B, Gururangan S, McLendon RE, Bigner DD, Lipp ES, Perreault S, Cho YJ, Grant G, Kim SK, Lee JY, Rao AAN, Giannini C, Li KKW, Ng HK, Yao Y, Kumabe T, Tominaga T, Grajkowska WA, Perek-Polnik M, Low DCY, Seow WT, Chang KTE, Mora J, Pollack IF, Hamilton RL, Leary S, Moore AS, Ingram WJ, Hallahan AR, Jouvet A, Fèvre-Montange M, Vasiljevic A, Faure-Conter C, Shofuda T, Kagawa N, Hashimoto N, Jabado N, Weil AG, Gayden T, Wataya T, Shalaby T, Grotzer M, Zitterbart K, Sterba J, Kren L, Hortobágyi T, Klekner A, László B, Pócza T, Hauser P, Schüller U, Jung S, Jang WY, French PJ, Kros JM, van Veelen MC, Massimi L, Leonard JR, Rubin JB, Vibhakar R, Chambless LB, Cooper MK, Thompson RC, Faria CC, Carvalho A, Nunes S, Pimentel J, Fan X, Muraszko KM, López-Aguilar E, Lyden D, Garzia L, Shih DJH, Kijima N, Schneider C, Adamski J, Northcott PA, Kool M, Jones DTW, Chan JA, Nikolic A, Garre ML, Van Meir EG, Osuka S, Olson JJ, Jahangiri A, Castro BA, Gupta N, Weiss WA, Moxon-Emre I, Mabbott DJ, Lassaletta A, Hawkins CE, Tabori U, Drake J, Kulkarni A, Dirks P, Rutka JT, Korshunov A, Pfister SM, Packer RJ, Ramaswamy V, Taylor MD.

Lancet Oncol. 2016 Apr;17(4):484-495. doi: 10.1016/S1470-2045(15)00581-1. Epub 2016 Mar 12.

3.

Medulloblastoma in China: clinicopathologic analyses of SHH, WNT, and non-SHH/WNT molecular subgroups reveal different therapeutic responses to adjuvant chemotherapy.

Zhang ZY, Xu J, Ren Y, Li KK, Ng HK, Mao Y, Zhong P, Yao Y, Zhou LF.

PLoS One. 2014 Jun 16;9(6):e99490. doi: 10.1371/journal.pone.0099490. eCollection 2014. Erratum in: PLoS One. 2014;9(8):e105742. PLoS One. 2014;9(9):e107855.

4.

Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.

Goschzik T, Schwalbe EC, Hicks D, Smith A, Zur Muehlen A, Figarella-Branger D, Doz F, Rutkowski S, Lannering B, Pietsch T, Clifford SC.

Lancet Oncol. 2018 Dec;19(12):1602-1616. doi: 10.1016/S1470-2045(18)30532-1. Epub 2018 Nov 1.

5.

Survival and prognostic factors in a series of adults with medulloblastomas.

Riffaud L, Saikali S, Leray E, Hamlat A, Haegelen C, Vauleon E, Lesimple T.

J Neurosurg. 2009 Sep;111(3):478-87. doi: 10.3171/2009.1.JNS081004.

PMID:
19231932
6.
7.

Metastatic medulloblastoma in adults: outcome of patients treated according to the HIT2000 protocol.

von Bueren AO, Friedrich C, von Hoff K, Kwiecien R, Müller K, Pietsch T, Warmuth-Metz M, Hau P, Benesch M, Kuehl J, Kortmann RD, Rutkowski S.

Eur J Cancer. 2015 Nov;51(16):2434-43. doi: 10.1016/j.ejca.2015.06.124. Epub 2015 Aug 5.

PMID:
26254812
8.

Primary postoperative chemotherapy without radiotherapy for treatment of brain tumours other than ependymoma in children under 3 years: results of the first UKCCSG/SIOP CNS 9204 trial.

Grundy RG, Wilne SH, Robinson KJ, Ironside JW, Cox T, Chong WK, Michalski A, Campbell RH, Bailey CC, Thorp N, Pizer B, Punt J, Walker DA, Ellison DW, Machin D; Children's Cancer and Leukaemia Group (formerly UKCCSG) Brain Tumour Committee.

Eur J Cancer. 2010 Jan;46(1):120-33. doi: 10.1016/j.ejca.2009.09.013.

PMID:
19818598
9.
10.

Chemotherapy for children with medulloblastoma.

Michiels EM, Schouten-Van Meeteren AY, Doz F, Janssens GO, van Dalen EC.

Cochrane Database Syst Rev. 2015 Jan 1;1:CD006678. doi: 10.1002/14651858.CD006678.pub2. Review.

PMID:
25879092
11.

Clinical characteristics and abandonment and outcome of treatment in 67 Chinese children with medulloblastoma.

Wang C, Yuan XJ, Jiang MW, Wang LF.

J Neurosurg Pediatr. 2016 Jan;17(1):49-56. doi: 10.3171/2015.5.PEDS1573. Epub 2015 Oct 9.

PMID:
26451721
12.

beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee.

Ellison DW, Onilude OE, Lindsey JC, Lusher ME, Weston CL, Taylor RE, Pearson AD, Clifford SC; United Kingdom Children's Cancer Study Group Brain Tumour Committee.

J Clin Oncol. 2005 Nov 1;23(31):7951-7.

PMID:
16258095
13.

Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy.

Packer RJ, Sutton LN, Elterman R, Lange B, Goldwein J, Nicholson HS, Mulne L, Boyett J, D'Angio G, Wechsler-Jentzsch K, et al.

J Neurosurg. 1994 Nov;81(5):690-8.

PMID:
7931615
14.

Postoperative Radiotherapy Patterns of Care and Survival Implications for Medulloblastoma in Young Children.

Kann BH, Park HS, Lester-Coll NH, Yeboa DN, Benitez V, Khan AJ, Bindra RS, Marks AM, Roberts KB.

JAMA Oncol. 2016 Dec 1;2(12):1574-1581. doi: 10.1001/jamaoncol.2016.2547. Erratum in: JAMA Oncol. 2016 Dec 1;2(12 ):1661.

PMID:
27491009
15.

Treatment of Children and Adolescents With Metastatic Medulloblastoma and Prognostic Relevance of Clinical and Biologic Parameters.

von Bueren AO, Kortmann RD, von Hoff K, Friedrich C, Mynarek M, Müller K, Goschzik T, Zur Mühlen A, Gerber N, Warmuth-Metz M, Soerensen N, Deinlein F, Benesch M, Zwiener I, Kwiecien R, Faldum A, Bode U, Fleischhack G, Hovestadt V, Kool M, Jones D, Northcott P, Kuehl J, Pfister S, Pietsch T, Rutkowski S.

J Clin Oncol. 2016 Dec;34(34):4151-4160. Epub 2016 Oct 31.

PMID:
27863192
16.

Medulloblastoma in children: a 32-year experience from a single institution.

Akyüz C, Varan A, Küpeli S, Akalan N, Söylemezoglu F, Zorlu F, Kutluk T, Büyükpamukçu M.

J Neurooncol. 2008 Oct;90(1):99-103. doi: 10.1007/s11060-008-9638-x. Epub 2008 Jun 20.

PMID:
18566744
17.

Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study.

Schwalbe EC, Lindsey JC, Nakjang S, Crosier S, Smith AJ, Hicks D, Rafiee G, Hill RM, Iliasova A, Stone T, Pizer B, Michalski A, Joshi A, Wharton SB, Jacques TS, Bailey S, Williamson D, Clifford SC.

Lancet Oncol. 2017 Jul;18(7):958-971. doi: 10.1016/S1470-2045(17)30243-7. Epub 2017 May 22.

18.

Medulloblastoma in adults : A retrospective single institution analysis.

Hadi I, Roengvoraphoj O, Niyazi M, Roeder F, Schüller U, Belka C, Nachbichler SB.

Strahlenther Onkol. 2018 Mar;194(3):225-234. doi: 10.1007/s00066-017-1235-5. Epub 2017 Nov 16.

PMID:
29147840
19.

Reproducibility of the NanoString 22-gene molecular subgroup assay for improved prognostic prediction of medulloblastoma.

Leal LF, Evangelista AF, de Paula FE, Caravina Almeida G, Carloni AC, Saggioro F, Stavale JN, Malheiros SMF, Mançano B, de Oliveira MA, Luu B, Neder L, Taylor MD, Reis RM.

Neuropathology. 2018 Oct;38(5):475-483. doi: 10.1111/neup.12508. Epub 2018 Aug 28.

PMID:
30155928
20.

Outcome and prognostic factors of desmoplastic medulloblastoma treated within a multidisciplinary treatment concept.

Rieken S, Gaiser T, Mohr A, Welzel T, Witt O, Kulozik AE, Wick W, Debus J, Combs SE.

BMC Cancer. 2010 Aug 23;10:450. doi: 10.1186/1471-2407-10-450.

Supplemental Content

Support Center